Member access

4-Traders Homepage  >  Shares  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Ranbaxy Laboratories Limited    RANBAXY   INE015A01028

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Ranbaxy Resumes Generic Lipitor Production for U.S.

02/22/2013 | 01:05pm US/Eastern

Ranbaxy Laboratories Ltd. (500359.BY) said Friday it has resumed manufacturing generic copies of the cholesterol-lowering drug Lipitor for the U.S. market, following a production suspension late last year after tiny glass particles were found in the product.

Ranbaxy voluntarily recalled about 480,000 bottles of generic Lipitor, also known as atorvastatin calcium, in the U.S. in November, after discovering the glass fragment problem.

An Indian unit of Japan's Daiichi Sankyo Co. (DSNKY, 4568.TO), Ranbaxy said Friday it's working with the U.S. Food and Drug Administration as it implements corrective actions designed to prevent future manufacturing problems.

Ranbaxy has commenced production of the drug substance for its atorvastatin product, as part of the first step toward resuming supplies to the U.S. market, the company said in a statement.

The recall didn't affect Ranbaxy's generic Lipitor product outside the U.S.

In January, Ranbaxy said it completed an investigation of the manufacturing problem that caused the glass particles to turn up in the product. The company previously said it suspected that a faulty tank at a facility in India caused the problem.

Ranbaxy was one of the biggest sellers of generic Lipitor in the U.S. after Pfizer Inc. (>> Pfizer Inc.) lost exclusivity for the branded product in late 2011.

But Ranbaxy's share of the generic Lipitor market has plunged to 2% from about 45% before the recall, according to J.P. Morgan, which cited data from IMS Health. Other generic companies including Mylan Inc. (>> Mylan Inc.) and Apotex Inc. have gained share of the generic Lipitor market.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Mylan Inc., Pfizer Inc.
Latest news on RANBAXY LABORATORIES LIMIT
1d ago RANBAXY LABORATORIES : posts 1st profit in 6 months
2d ago Cipher Reports Financial Results for Q3 2014
2d ago Ranbaxy sees first profit in six qtrs on Diovan sales
2d ago RANBAXY TURNS AROUND, POSTS Rs478-CRORE PROFIT IN Q2
3d ago RANBAXY LABORATORIES : Q2 FY 2015 Sales Rs.32,180 Mn. H1 FY2015 Sales Rs.55,902 ..
3d ago Ranbaxy might lose nexium exclusivity
3d ago RANBAXY LABORATORIES : Q2 fy 2015 sales rs.32,180 mn. h1 fy2015 sales rs.55,902 ..
4d ago Ranbaxy surges after profit, Sun Pharma also gains
4d ago RANBAXY LABORATORIES : return to health lifts the stock higher
4d ago Sensex jumps 128 points; Ranbaxy, Sun Pharma surge
Advertisement
Chart
Duration : Period :
Ranbaxy Laboratories Limit Technical Analysis Chart | RANBAXY | INE015A01028 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF